[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100367481":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":78,"collaborators":58,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":58,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":58,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":63,"whyStopped":58,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"IVF: dual trigger","ACTIVE_COMPARATOR","When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.",[13],"Drug: IVF: Decapeptyl and hCG",{"label":15,"type":16,"description":17,"interventionNames":18},"IVF: hCG trigger","PLACEBO_COMPARATOR","When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.",[19],"Drug: IVF: hCG and normal saline",{"label":21,"type":10,"description":22,"interventionNames":23},"FET: agonist","On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.",[24],"Drug: FET: Decapeptyl",{"label":26,"type":16,"description":27,"interventionNames":28},"FET: control","On the day of FET, normal saline will be injected subcutaneously.",[29],"Drug: FET: Normal Saline",[31,37,42,46],{"type":32,"name":33,"description":11,"armGroupLabels":34,"otherNames":35},"DRUG","IVF: Decapeptyl and hCG",[9],[36],"IVF: hCG",{"type":32,"name":38,"description":22,"armGroupLabels":39,"otherNames":40},"FET: Decapeptyl",[21],[41],"FET: normal saline",{"type":32,"name":43,"description":17,"armGroupLabels":44,"otherNames":45},"IVF: hCG and normal saline",[15],[33],{"type":32,"name":47,"description":27,"armGroupLabels":48,"otherNames":49},"FET: Normal Saline",[26],[38],[51],{"name":52,"affiliation":5,"role":53},"Ernest HY Ng, MD","PRINCIPAL_INVESTIGATOR",[55],{"name":52,"role":56,"phone":57,"phoneExt":58,"email":59},"CONTACT","852-28553400",null,"nghye@hku.hk",[61],{"facility":62,"status":63,"city":64,"state":64,"zip":58,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Department of Obstetrics and Gynaecology","RECRUITING","Hong Kong","China","CN",{"type":68,"coordinates":69},"Point",[70,71],114.17469,22.27832,{"lat":71,"lon":70},[74,77],{"name":75,"role":56,"phone":76,"phoneExt":58,"email":59},"Ernest HY NG, MD","852-22553400",{"name":75,"role":53,"phone":58,"phoneExt":58,"email":58},{"type":79,"investigatorFullName":58,"investigatorTitle":58,"investigatorAffiliation":58,"oldNameTitle":58,"oldOrganization":58},"SPONSOR","100367481","phase-3-gnrh-agonist-for-dual-trigger-in-ivf-and-for-luteal-phase-support-in-fet-100367481",false,"NCT04064840","GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET","Gonadotrophin Releasing Hormone Agonist for Dual Trigger in in Vitro Fertilization and for Luteal Phase Support in Frozen-thawed Embryo Transfer","IVF\n\nInclusion criteria:\n\n\\- Women aged \\\u003C43 years at the time of IVF treatment\n\nExclusion criteria:\n\n* Preimplantation genetic diagnosis treatment\n* Use of donor oocytes or donor embryos\n* Hydrosalpinx shown on pelvic scanning and not surgically treated\n* Women at risk of OHSS\n\nFET\n\nInclusion criteria:\n\n* Women aged \\\u003C43 years at the time of IVF treatment\n* Replacing early cleavage embryos or blastocysts after thawing\n* FET in natural cycles\n\nExclusion criteria:\n\n* Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient\n* Preimplantation genetic diagnosis treatment\n* Use of donor oocytes or donor embryos\n* Hydrosalpinx shown on pelvic scanning and not surgically treated","FEMALE","18 Years","42 Years",{"count":91,"type":92},784,"ESTIMATED","INTERVENTIONAL",[95],"PHASE3","The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.",[98],"Subfertility",[100,101,102,103,104,105,106],"subfertility","IVF","FET","dual trigger","luteal phase support","Gonadotrophin releasing hormone agonist","live birth rate","2026-05-14",{"date":109,"type":110},"2026-05-15","ACTUAL",{"date":112,"type":110},"2019-09-01",{"date":114,"type":92},"2026-05-30",{"name":5,"class":6},1]